State of Nordic
Biopharma
1 July to 30 September 2026
The Nordic index ended flat in a quarter of licensing deals and phase III misses
The Nordic HC SEK GI rose 0.27 per cent in Q3 2026 while the NASDAQ Biotechnology Index gained 8.37 per cent. The two largest Nordic companies each took a phase III miss in July, then delivered on earnings: Novo raised its full-year outlook and AstraZeneca reconfirmed guidance. Three of Q3's four largest transactions were licences.
16 pages of Nordic biopharma intelligence
Executive summary
The quarter's defining events, the top five data points and a sentiment snapshot.
Market performance
Three-index dashboard with the weekly comparison, plus the 12 largest movers (six gainers, six decliners) with driver commentary.
Top events and catalysts
Each typed and referenced to its source.
Sector themes
Licensing as the route to value, CagriSema's head-to-head win in type 2 diabetes, Leqembi's launches and a split funding market.
Capital markets activity
Equity financings, buybacks, M&A and partnerships, wind-downs and exits: who raised, and on what terms.
Catalyst watch
Binary, asymmetric and incremental catalysts from Q4 2026 to H1 2027, including two December PDUFA dates, plus the status of every catalyst flagged in the Q1 and Q2 reports.
Investor insights
Six read-throughs for Q4.
References
143 primary sources with clickable links.
Know what moved and what moves next
See what moved listed Nordic biopharma in Q3 and which dated events decide Q4.
- Why licences set the prices for Nordic biotech assets in Q3
- How Novo lost ZEUS, won REIMAGINE 5 and still raised its outlook
- How Leqembi moved from licensing deals to a subcutaneous US launch
- Which Swedish rights issues needed their guarantors, and which Oslo placements cleared at size
- The quarter's biggest movers, from Nanexa's +177 per cent to rights-issue falls, with driver commentary
- The Q4 catalyst calendar, led by two December PDUFA dates
